Skip to main content
SpringerLink
Log in

Primary and Secondary Hyperparathyroidism Testing and Assays

  • Chapter
  • First Online:
Handbook of Parathyroid Diseases

  • 1259 Accesses

Abstract

Once considered rare disorders, primary (p) and secondary (s) hyperparathyroidism (HPT), are now frequently seen in all parts of the world in relation to the development of routine total calcium measurement and the availability of accurate parathyroid hormone (PTH) and 25-hydroxy-vitamin D (25(OH)D) assays. Both conditions can present with a very different biochemical profile, but normocalcemic primary HPT (pHPT) can also be very difficult to distinguish from mild sHPT. In the following chapter, we analyze which biochemical tests are best suited to investigate and diagnose these disorders.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Harrap JS, Barley JE, Woodhead JS. Incidence of hypercalcemia and primary hyperparathyroidism in relation to biochemical profile. J Clin Pathol. 1982;35:395–400.

    Article  Google Scholar 

  2. Lafferty FW. Primary hyperparathyroidism. Changing clinical spectrum, prevalence of hypertension, and discriminant analysis of laboratory tests. Arch Intern Med. 1981;141:1761–6.

    Article  PubMed  CAS  Google Scholar 

  3. Lacher DA. Comparison of nonparametric recursive partitioning to parametric discriminant analyses in laboratory differentiation of hypercalcemia. Clin Chim Acta. 1991;204:199–208.

    Article  PubMed  CAS  Google Scholar 

  4. Gardin JP, Paillard M. Normocalcemic primary hyperparathyroidism: resistance to PTH effect on tubular reabsorption of calcium. Miner Electrolyte Metab. 1984;10:301–8.

    PubMed  CAS  Google Scholar 

  5. Johansson H, Thorén L, Werner I, Grimelius L. Normocalcemic hyperparathyroidism, kidney stones, and idiopathic hypercalciuria. Surgery. 1975;77:691–6.

    PubMed  CAS  Google Scholar 

  6. Maruani G, Hertig A, Paillard M, Houillier P. Normocalcemic primary hyperparathyroidism: evidence for a generalized target-tissue resistance to parathyroid hormone. J Clin Endocrinol Metab. 2003;88:4641–8.

    Article  PubMed  CAS  Google Scholar 

  7. Yang AH, Hsu CW, Chen JY, Tseng LM, Won GS, Lee CH. Normocalcemic primary hyperparathyroidism in patients with recurrent kidney stones: pathological analysis of parathyroid glands. Virchows Arch. 2006;449:62–8.

    Article  PubMed  Google Scholar 

  8. Monchik JM, Gorgin E. Normocalcemic hyperparathyroidism in patients with osteoporosis. Surgery. 2004;136:1242–6.

    Article  PubMed  Google Scholar 

  9. McLeod MK, Monchik JM, Martin HF. The role of ionized calcium in the diagnosis of subtle hypercalcemia in symptomatic primary hyperparathyroidism. Surgery. 1994;95:667–73.

    Google Scholar 

  10. Hagström E, Lundgren E, Rastad J, Hellman P. Metabolic abnormalities in patient with normocalcemic hyperparathyroidism detected at a population-based screening. Eur J Endocrinol. 2006;155:33–9.

    Article  PubMed  Google Scholar 

  11. Bilezikian JP, Khan A, Potts Jr JT. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. J Clin Endocrinol Metab. 2009;94:335–9.

    Article  PubMed  CAS  Google Scholar 

  12. Gao P, D’Amour P. Evolution of the parathyroid hormone (PTH) assay. Importance of circulating PTH immunoheterogeneity and of its regulation. Clin Lab. 2005;51:21–9.

    PubMed  CAS  Google Scholar 

  13. Hackeng WLH, Lips P, Netelenbos CJ. Clinical implications of estimation of intact parathyroid hormone (PTH) versus total immunoreactive PTH in normal subjects and hyperparathyroid patients. J Clin Endocrinol Metab. 1986;63:447–53.

    Article  PubMed  CAS  Google Scholar 

  14. St John A, Davies C, Riley WJ, Kent GN, Brown RC, Aston JP, Weeks I, Woodhead JS. Comparison of the performance and clinical utility of a carboxy-terminal assay and an intact assay for parathyroid hormone. Clin Chim Acta. 1988;178:215–23.

    Article  PubMed  CAS  Google Scholar 

  15. Lepage R, Whittom S, Bertrand S, Bahsali G, D’Amour P. Superiority of dynamic over static reference intervals for intact, midmolecule, and C-terminal parathyrin in evaluating calcemic disorders. Clin Chem. 1992;38:2129–35.

    PubMed  CAS  Google Scholar 

  16. Brossard JH, Whittom S, Lepage R, D’Amour P. Carboxyl-terminal fragments of parathyroid hormone are not secreted preferentially in primary hyperparathyroidism as they are in other causes of hypercalcemia. J Clin Endocrinol Metab. 1993;77:413–9.

    Article  PubMed  CAS  Google Scholar 

  17. Nussbaum SR, Zahradnik RJ, Lavigne JR, Brennan GL, Nozawa-Ung K, Kim LY, Keutmann HT, Wang CA, Potts Jr JT, Segre GV. Highly sensitive two-site immunoradiometric assay of parathyrin, and its clinical utility in evaluating patients with hypercalcemia. Clin Chem. 1987;33:1365–7.

    Google Scholar 

  18. Brossard JH, Cloutier M, Roy L, Lepage R, D’Amour P. Accumulation of non-(1–84) molecular form of parathyroid hormone (PTH) detected by intact PTH assay in renal failure: importance in the interpretation of PTH values. J Clin Endocrinol Metab. 1996;81:3923–9.

    Article  PubMed  CAS  Google Scholar 

  19. Souberbielle JC, Boutten A, Carlier MC, Chevenne D, Coumaros G, Lawson-Body E, Massart C, Monge M, Myara J, Parent X, Plouvier E, Houillier P. Inter-method variability in PTH measurement: implication for the care of CKD patients. Kidney Int. 2006;70:345–50.

    Article  PubMed  CAS  Google Scholar 

  20. Brossard JH, Cardinal H, Roy L, Lepage R, Rousseau L, Dorais C, D’Amour P. Influence of glomerular filtration rate on intact parathyroid hormone levels in renal failure patients: role of non-(1–84) PTH detected by intact PTH assays. Clin Chem. 2000;46:697–703.

    PubMed  CAS  Google Scholar 

  21. Lowe H, McMahon DJ, Rubin MR, Bilezikian JP, Silverberg SJ. Normocalcemic primary hyperparathyroidism: further characterization of a new clinical phenotype. J Clin Endocrinol Metab. 2007;92:3001–5.

    Article  PubMed  CAS  Google Scholar 

  22. John MR, Goodman WG, Gao P, Cantor TL, Salusky IB, Jüppner H. A novel immunoradiometric assay detects full-length human PTH but not amino-terminally truncated fragments: implications for PTH measurements in renal failure. J Clin Endocrinol Metab. 1999;84:4287–90.

    Article  PubMed  CAS  Google Scholar 

  23. Gao P, Scheibel S, D’Amour P, John MR, Rao SD, Schmidt-Gayk H, Cantor TL. Development of a novel immunoradiometric assay exclusively for biologically active whole parathyroid hormone 1–84: implications for improvement of accurate assessment of parathyroid function. J Bone Miner Res. 2001;16:605–14.

    Article  PubMed  CAS  Google Scholar 

  24. D’Amour P, Brossard JH, Rousseau L, Roy L, Gao P, Cantor T. Amino-terminal form of parathyroid hormone (PTH) with immunologic similarities to hPTH(1–84) is overproduced in primary and secondary hyperparathyroidism. Clin Chem. 2003;49:2037–44.

    Article  PubMed  Google Scholar 

  25. D’Amour P, Brossard JH, Rousseau L, Nguyen-Yamamoto L, Nassif E, Lazure C, Gauthier D, Lavigne JR, Zahradnik RJ. Structure of non-(1–84) PTH fragments secreted by parathyroid glands in primary and secondary hyperparathyroidism. Kidney Int. 2005;68:998–1007.

    Article  PubMed  Google Scholar 

  26. D’Amour P, Räkel A, Brossard JH, Rousseau L, Albert C, Cantor T. Acute regulation of circulating parathyroid hormone (PTH) molecular forms by calcium: utility of PTH fragments/PTH(1–84) ratios derived from three generations of PTH assays. J Clin Endocrinol Metab. 2006;91:283–9.

    Article  PubMed  Google Scholar 

  27. Räkel A, Brossard JH, Patenaude JV, Albert C, Nassif E, Cantor T, Rousseau L, D’Amour P. Overproduction of an amino-terminal form of PTH distinct from human PTH(1–84) in a case of severe primary hyperparathyroidism: influence of medical treatment and surgery. Clin Endocrinol. 2005;62:721–7.

    Article  Google Scholar 

  28. Rubin MR, Silverberg SJ, D’Amour P, Brossard JH, Rousseau L, Sliney Jr J, Cantor T, Bilezikian JP. An N-terminal molecular form of parathyroid hormone (PTH) distinct from hPTH(1 84) is overproduced in parathyroid carcinoma. Clin Chem. 2007;53:1470–6.

    Article  PubMed  CAS  Google Scholar 

  29. Boudou P, Ibrahim F, Cormier C, Sarfati E, Souberbielle JC. Unexpected serum parathyroid hormone profiles in some patients with primary hyperparathyroidism. Clin Chem. 2006;52: 757–60.

    Article  PubMed  CAS  Google Scholar 

  30. Silverberg SJ, Gao P, Brown I, LoGerfo P, Cantor TL, Bilezikian JP. Clinical utility of an immunoradiometric assay for parathyroid hormone (1–84) in primary hyperparathyroidism. J Clin Endocrinol Metab. 2003;88:4725–30.

    Article  PubMed  CAS  Google Scholar 

  31. Souberbielle JC, Boudou F, Cormier C. Lessons from second- and third-generation parathyroid hormone assays in primary hyperparathyroidism. J Endocrinol Invest. 2008;31:463–9.

    PubMed  CAS  Google Scholar 

  32. Eastell R, Arnold A, Brandi ML, Brown EM, D’Amour P, Hanley DA, Rao DS, Rubin MR, Goltzman D, Silverberg SJ, Marx SJ, Peacock M, Mosekilde L, Bouillon R, Lewiecki EM. Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab. 2009;94:340–50.

    Article  PubMed  CAS  Google Scholar 

  33. Yamashita H, Noguchi S, Uchino S, Watanabe S, Murakami T, Ogawa T, Masatsugu T, Takamatsu Y, Miyatake E, Yamashita H. Influence of renal function on clinico-pathologic features of primary hyperparathyroidism. Eur J Endocrinol. 2003;148:597–602.

    Article  PubMed  CAS  Google Scholar 

  34. Pollak MR, Brown EM, Chou YH, Hebert SC, Marx SJ, Steinmann B, Levi T, Seidman CE, Seidman JG. Mutations in the human Ca(2+)-sensing receptor gene cause familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Cell. 1993;75:1297–303.

    Article  PubMed  CAS  Google Scholar 

  35. Pallais JC, Kifor O, Chen YB, Slovik D, Brown EM. Acquired hypocalciuric hypercalcemia due to autoantibodies against the calcium-sensing receptor. N Engl J Med. 2004;351: 362–9.

    Article  PubMed  CAS  Google Scholar 

  36. Marx SJ, Attie MF, Levine MA, Spiegel AM, Downs RW, Lasker RD. The hypocalciuric or benign variant of familial hypercalcemia: clinical and biochemical features in fifteen kindreds. Medicine. 1981;60:397–412.

    Article  PubMed  CAS  Google Scholar 

  37. Miller PD, Dubovsky SL, Schrier RW, McDonald KM, Arnaud C. Hypocalciuric effect of lithium in man. Miner Electrolyte Metab. 1978;1:3–11.

    CAS  Google Scholar 

  38. Rao DS, Honasoge M, Divine GW, Phillips ER, Lee MW, Ansari MR, Talpos GB, Parfitt AM. Effect of vitamin D nutrition on parathyroid adenoma weight: pathogenetic and clinical implications. J Clin Endocrinol Metab. 2000;85:1054–8.

    Article  PubMed  CAS  Google Scholar 

  39. Clements MR, Davies M, Fraser DR, Lumb GA, Mawer EB, Adams PH. Metabolic inactivation of vitamin D is enhanced in primary hyperparathyroidism. Clin Sci. 1987;73:659–64.

    PubMed  CAS  Google Scholar 

  40. Coen G, Bondatti F, de Matteis A, Ballanti P, Mazzaferro S, Sardella D, Smacchi A. Severe vitamin D deficiency in a case of primary hyperparathyroidism caused by parathyroid lipoadenoma, effect of 25OHD3 treatment. Miner Electrolyte Metab. 1989;15:332–7.

    PubMed  CAS  Google Scholar 

  41. Mithal A, Bandeira F, Meng X, Silverberg SJ, Shi Y, Mishra SK, Griz L, Macedo G, Celdas G, Bandeira C, Bilezikian JB, Rao DS. Clinical presentation of primary hyperparathyroidism: India, Brazil and China. In: Bilezikian JP, Marcus R, Levine MA, editors. The parathyroids. London: Academic Press; 2001. p. 375–86. Chapter 22.

    Google Scholar 

  42. Brossard JH, Garon J, Lepage R, Gascon-Barré M, D’Amour P. Inhibition of 1,25(OH)2D production by hypercalcemia in osteitis fibrosa cystica: influence on parathyroid hormone secretion and hungry bone disease. Bone Miner. 1993;23:15–26.

    Article  PubMed  CAS  Google Scholar 

  43. Grey A, Lucas J, Horne A, Gamble G, Davidson JS, Reid IR. Vitamin D repletion in patients with primary hyperparathyroidism and coexistent vitamin D insufficiency. J Clin Endocrinol Metab. 2005;90:2122–6.

    Article  PubMed  CAS  Google Scholar 

  44. Heath III H. Familial benign hypocalciuric hypercalcemia. Endocrinol Metab Clin North Am. 1989;18:723–40.

    PubMed  Google Scholar 

  45. Cloutier M, Gagnon Y, Brossard JH, Gascon-Barré M, D’Amour P. Adaptation of parathyroid function to IV 1,25-dihydroxyvitamin D3 or partial parathyroidectomy in normal dogs. J Endocrinol. 1997;155:133–41.

    Article  PubMed  CAS  Google Scholar 

  46. D’Amour P, Faughnan M, Paradis E, Lepage R, Ste-Marie LG, Brossard JH. An increased C-PTH level in a normocalcemic individual may reflect an adaptation to an increased parathyroid function. J Bone Miner Res. 1996;11(suppl 1: S493):T7361. Abstract.

    Google Scholar 

  47. Nguyen-Yamamoto L, Rousseau L, Brossard JH, Lepage R, D’Amour P. Synthetic carboxyl-terminal fragments of PTH decrease ionized calcium concentration in rats by acting on a receptor different from the PTH/PTHrP receptor. Endocrinology. 2001;142:1386–92.

    Article  PubMed  CAS  Google Scholar 

  48. Usatii M, Rousseau L, Demers C, Petit JL, Brossard JH, Gascon-Barré M, Lavigne JR, Zahradnik RJ, Nemeth EF, D’Amour P. Parathyroid hormone fragments inhibit active hormone and hypocalcemia-induced 1,25(OH)2D synthesis. Kidney Int. 2007;72:1330–5.

    Article  PubMed  CAS  Google Scholar 

  49. Slatopolsky E, Finch J, Clay P, Martin D, Sicard G, Singera G, Gao P, Cantor T, Dusso A. A novel mechanism for skeletal resistance in uremia. Kidney Int. 2000;58:753–61.

    PubMed  CAS  Google Scholar 

  50. Andress DL, Endres DB, Maloney NA, Kopp JB, Coburn JW, Sherrard DJ. Comparison of parathyroid hormone assays with bone histomorphometry in renal osteodystrophy. J Clin Endocrinol Metab. 1986;63:1163–9.

    Article  PubMed  CAS  Google Scholar 

  51. Cohen Solal Me, Sebert JL, Boudailliez B, Marie A, Moriniere P, Gueris J, Bouillon R, Fournier A. Comparison of intact, midregion and carboxy terminal assays of parathyroid hormone for the diagnosis of bone disease in hemodialyzed patients. J Clin Endocrinol Metab. 1991;73:516–24.

    Article  Google Scholar 

  52. Coen G, Mazzaferro S, Ballanti P, Bonucci E, Cinotti GA, Fondi G, Manni M, Pasguali M, Perruzza I, Sardella D, Faggi F. Two-site immunoradiometric intact parathyroid hormone assay versus C-terminal parathyroid hormone in predicting osteodystrophic bone lesions in predialysis chronic renal failure. J Lab Clin Med. 1993;122:103–9.

    PubMed  CAS  Google Scholar 

  53. D’Amour P. Lessons from second- and third-generation PTH assays in renal failure patients. J Endocrinol Invest. 2008;31:459–62.

    Google Scholar 

  54. Murray TM, Rao LG, Divieti P, Bringhurst FR. Parathyroid hormone secretion and action: evidence for discrete receptors for the carboxyl-terminal region and related biological actions of carboxyl-terminal ligands. Endocrine Rev. 2005;26:78–113.

    Article  CAS  Google Scholar 

  55. Divieti P, John MR, Juppner H, Bringhurst FR. Human PTH-(7–84) inhibits bone resorption in vitro via actions independent of the type 1 PTH/PTHrP receptor. Endocrinology. 2002;143: 171–6.

    Article  PubMed  CAS  Google Scholar 

  56. Divieti P, Geller AI, Suliman G, Juppner H, Bringhurst FR. Receptors specific for the carboxyl-terminal region of parathyroid hormone on bone-derived cells: determinants of ligand binding and bioactivity. Endocrinology. 2005;146:1863–70.

    Article  PubMed  CAS  Google Scholar 

  57. Monier-Faugère MC, Geng Z, Mawad H, Friedler RM, Gao P, Cantor TL, Malluche HH. Improved assessment of bone turnover by the PTH-(1–84)/large C-PTH fragments ratio in ESRD patients. Kidney Int. 2001;60:1460–8.

    Article  PubMed  Google Scholar 

  58. Coen G, Bonucci E, Ballanti P, Balducci A, Calabria S, Nicolai GA, Fischer MS, Lifrieri F, Manni M, Morosetti M, Moscaritolo E, Sardella D. PTH 1–84 and PTH(7–84) in the non-invasive diagnosis of renal bone disease. Am J Kidney Dis. 2002;40:348–54.

    Article  PubMed  CAS  Google Scholar 

  59. Salusky IB, Goodman WG, Kuizon BD, Lavigne JR, Zalvranik RJ, Gales B, Wang JH, Elashaff RM, Juppner H. Similar predictive value of bone turnover using first- and second-generation immunometric PTH assays in pediatric patients treated with peritoneal dialysis. Kidney Int. 2003;63:1801–8.

    Article  PubMed  CAS  Google Scholar 

  60. Kollar H, Zitt E, Staudacher G, Neyer U, Mayer G, Rosenkranz AR. Variable parathyroid hormone(1–84)/carboxyl-terminal PTH ratios detected by 4 novel parathyroid hormone assays. Clin Nephrol. 2004;61:337–43.

    Google Scholar 

  61. Heaney RP, Dowell MS, Hale CA, Bendich A. Calcium absorption varies within the reference range for serum 25-hydroxyvitamin D. J Am Coll Nutr. 2003;22:142–6.

    PubMed  CAS  Google Scholar 

  62. Steingrimsdottir L, Gunnarsson O, Indridason OS, Franzson L, Sigurdsson G. Relationship between serum parathyroid hormone levels, vitamin D sufficiency and calcium intake. J Am Med Assoc. 2005;294:2336–41.

    Article  CAS  Google Scholar 

  63. Adami S, Viapiana O, Gatti D, Idolazzi L, Rossini M. Relationship between serum parathyroid hormone, vitamin D sufficiency, age, and calcium intake. Bone. 2008;42:267–70.

    Article  PubMed  CAS  Google Scholar 

  64. Souberbielle JC, Cormier C, Kindermans C, Gao P, Cantor T, Forette F, Baulieu EE. Vitamin D status and redefining serum parathyroid hormone reference range in the elderly. J Clin Endocrinol Metab. 2001;86:3086–90.

    Article  PubMed  CAS  Google Scholar 

  65. Lips P, Pluijm SMF, Smit JH, Van Schoor NM. Vitamin D status and the threshold for secondary hyperparathyroidism in the longitudinal aging study Amsterdam (LASA). Bone. 2005;36(suppl):S141. Abstract.

    Google Scholar 

  66. González EA, Sachdeva A, Oliver DA, Martin KJ. Vitamin D insufficiency and deficiency in chronic kidney disease. Am J Nephrol. 2004;24:503–10.

    Article  PubMed  Google Scholar 

  67. Mucsi I, Almási C, Deák G, Marton A, Ambrus C, Berta K, Lakatos P, Szabó A, Horváth C. Serum 25(OH)-vitamin D levels and bone metabolism in patients on maintenance hemodialysis. Clin Nephrol. 2005;64:288–94.

    PubMed  CAS  Google Scholar 

  68. Taskapan H, Ersoy FF, Passadakis PS. Severe vitamin D deficiency in chronic renal failure patients on peritoneal dialysis. Clin Nephrol. 2006;66:247–55.

    PubMed  CAS  Google Scholar 

  69. Zehnder D, Landray MJ, Wheeler DC, Fraser W, Blackwell L, Nuttall S, Hughes SV, Townend J, Ferro C, Baigent C, Hewison M. Cross-sectional analysis of abnormalities of mineral homeostasis, vitamin D and parathyroid hormone in a cohort of pre-dialysis patients. The chronic renal impairment in Birmingham (CRIB) study. Nephron Clin Pract. 2007;107:C109–16.

    Article  PubMed  CAS  Google Scholar 

  70. Saclier DM, Magee CC. Prevalence of 25(OH) vitamin D (calcidiol) deficiency at time of renal transplantation: a prospective study. Clin Transplant. 2007;21:683–8.

    Google Scholar 

  71. Naveh-Many T, Friedlaender MM, Mayer H, Silver J. Calcium regulates parathyroid hormone messenger ribonucleic acid (mRNA), but not calcitonin mRNA in vivo in the rat. Dominant role of 1,25-dihydroxyvitamin D. Endocrinology. 1989;125:275–80.

    Article  PubMed  CAS  Google Scholar 

  72. Moallem E, Kilav R, Silver J, Naveh-Many T. RNA-protein binding and post-transcriptional regulation of parathyroid hormone gene expression by calcium and phosphate. J Biol Chem. 1998;273:5253–9.

    Article  PubMed  CAS  Google Scholar 

  73. Robertson WG. Urinary excretion of calcium phosphorus and magnesium. In: Nordin BEC, editor. Calcium phosphate and magnesium metabolism. Clinical physiology and diagnostic procedures. Edinburgh: Churchill Livingstone; 1976. p. 120. Chapter 3.

    Google Scholar 

  74. Bringhurst FR. Physiologic actions of PTH and PTHrP. II. Renal actions. In: Bilezikian JP, Marcus R, Levine MA, editors. The parathyroids: basic and clinical concepts. San Diego, USA: Academic Press; 2001. p. 227–44. Chapter 14.

    Google Scholar 

  75. Estep H, Shaw WA, Watlington C, Hobe R, Holland W, Tucker SG. Hypocalcemia due to hypomagnesemia and reversible parathyroid hormone unresponsiveness. J Clin Endocrinol Metab. 1969;29:842–8.

    Article  PubMed  CAS  Google Scholar 

  76. Suh SM, Tashjian Jr AH, Matsuo N, Parkinson DK, Fraser D. Pathogenesis of hypocalcemia in primary hypomagnesemia: normal end-organ responsiveness to parathyroid hormone, impaired parathyroid gland function. J Clin Invest. 1973;52:153–60.

    Article  PubMed  CAS  Google Scholar 

  77. Anast CS, Winnacker JL, Forte LR, Burns TW. Impaired release of parathyroid hormone in magnesium deficiency. J Clin Endocrinol Metab. 1976;42:707–17.

    Article  PubMed  CAS  Google Scholar 

  78. Rude RK, Oldham SB, Sharp Jr CF, Singer FR. Parathyroid hormone secretion in magnesium deficiency. J Clin Endocrinol Metab. 1978;47:800–6.

    Article  PubMed  CAS  Google Scholar 

  79. Sahota O, Mundey MK, San P, Godber IM, Hosking DJ. Vitamin D insufficiency and the blunted PTH response in established osteoporosis: the role of magnesium deficiency. Osteoporos Int. 2006;17:1013–21.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Centre de recherche, Centre hospitalier de l’Université de Montréal (CHUM)-Hôpital Saint-Luc, Université de Montréal, Montreal, QC, Canada

    Jean-Hugues Brossard M.D. & Pierre D’Amour M.D.

Authors
  1. Jean-Hugues Brossard M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pierre D’Amour M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jean-Hugues Brossard M.D. .

Editor information

Editors and Affiliations

  1. , Dept of Endocrinology and Metabolism, McMaster University, [not given], Hamilton, L8S4L8, Ontario, Canada

    Aliya A. Khan, MD

  2. Mt. Zion Medical Center, Dept. Surgery, University of California, San Francisco, Divisadero St. 1600, San Francisco, 94115, California, USA

    Orlo H. Clark

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Brossard, JH., D’Amour, P. (2012). Primary and Secondary Hyperparathyroidism Testing and Assays. In: Khan, MD, A., Clark, O. (eds) Handbook of Parathyroid Diseases. Springer, Boston, MA. https://doi.org/10.1007/978-1-4614-2164-1_3

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-2164-1_3

  • Published:

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4614-2163-4

  • Online ISBN: 978-1-4614-2164-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation